Eucrisa

(Crisaborole)

ApprovedSmall molecule

AAnacor

Eucrisa is one of 51 small molecule programs targeting Atopic Dermatitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Atopic DermatitisCompleted

Seborrheic DermatitisCompleted

Atopic DermatitisApproved

Completed

Seborrheic DermatitisApproved

Completed

Competition

Competitive Landscape

127 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Cytosar

Teva

Phase 3

1 2

Fludara

Sanofi

Phase 3

1 3

Adtralza

LEO Pharma

Phase 3

16 4

Eucrisa

AAnacor

Approved

4 5

Amlitelimab

Sanofi

Phase 3

2 6

DUPIXENT

Regeneron

Phase 3

1 7

Certolizumab

Johnson & Johnson

Phase 3

1 8

Jaktinib

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3

4 9

ICP-332

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

2 10

VC005

JJiangsu vcare pharmaceutical technology co., LTD

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Post-ApprovalNot yet recruiting

Atopic Dermatitis

NCT07352566

Clinical

Trials by Indication[1]

Atopic Dermatitis4 trials

Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis

Completed· Pfizer logo

Pfizer·Phase 3·NCT04360187·391 enrolled

ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis

Completed·UUniversity of Rochester·Phase 3·NCT03645057·92 enrolled

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not yet recruiting·UUniversity of California, San Francisco·Phase 4·NCT07352566·10 enrolled

Show 1 more trial

Response of Children With Atopic Dermatitis (Eczema) to Eucrisa

Completed·—·Phase 4·NCT04023084·30 enrolled

Alopecia Areata1 trial

Topical Crisaborole in Patients with Alopecia Areata

Withdrawn·TTufts Medical Center·Phase 2·NCT04299503

Dermatitis1 trial

Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis

Completed· Pfizer logo

Pfizer·Phase 2·NCT04091087·66 enrolled

Toxicity1 trial

Crisaborole Ointment for Skin Toxicity Induced by Cetuximab

Unknown status·SSun Yat-sen University·Phase 2·NCT06118047·33 enrolled

Atopic Eczema1 trial

Skin bioMARkers for Atopic Eczema Therapy Evaluation

Completed·SSheffield Teaching Hospitals NHS Foundation Trust·Phase 2·NCT04194814·37 enrolled

4 more indications

Seborrheic Dermatitis1 trial

A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis

Completed·UUniversity of Alabama at Birmingham·Phase 4·NCT03567980·30 enrolled

Steroid1 trial

Steroid-reducing Effects of Crisaborole

Completed·JJohns Hopkins University·Phase 4·NCT03832010·24 enrolled

Skin1 trial

Wearable Skin Sensors to Assess Nocturnal Scratch Behavior

Completed·NNorthwestern University··NCT03770858·23 enrolled

Pilot Study1 trial

Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

Completed·—·Phase 2·NCT03351114·8 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 14, 2016

EUCRISA

NDA NDA207695

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Crisaborole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Crisaborole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Crisaborole. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA207695). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Eucrisa. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Anacor company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AAnacor

Patent Landscape[5]

Patent Cliff

Feb 16, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8501712Feb 16, 2027

9682092Feb 16, 2027

9682092*PEDAug 16, 2027

8501712*PEDAug 16, 2027

8039451Jun 29, 2029

3 more patents

8039451*PEDDec 29, 2029

8168614Jan 20, 2030

8168614*PEDJul 20, 2030

Eucrisa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Atopic Dermatitis4 trials

Alopecia Areata1 trial

Dermatitis1 trial

Toxicity1 trial

Atopic Eczema1 trial

Seborrheic Dermatitis1 trial

Steroid1 trial

Skin1 trial

Pilot Study1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News